Axalta Coating Systems (NYSE:AXTA) Rating Lowered to Hold at Wall Street Zen
by Renee Jackson · The Cerbat GemAxalta Coating Systems (NYSE:AXTA – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.
Several other equities research analysts also recently weighed in on the company. KeyCorp reiterated an “overweight” rating on shares of Axalta Coating Systems in a report on Monday, October 5th. JPMorgan Chase & Co. increased their price target on shares of Axalta Coating Systems from $33.00 to $34.00 and gave the company a “neutral” rating in a report on Friday. UBS Group reduced their target price on shares of Axalta Coating Systems from $39.00 to $36.00 and set a “neutral” rating on the stock in a research report on Monday, October 5th. Royal Bank Of Canada increased their price objective on Axalta Coating Systems from $34.00 to $36.00 and gave the company a “sector perform” rating in a research report on Wednesday, July 8th. Finally, Weiss Ratings upgraded shares of Axalta Coating Systems from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, October 16th. Five investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $38.55.
Get Our Latest Stock Report on Axalta Coating Systems
Axalta Coating Systems Trading Down 0.2%
NYSE:AXTA opened at $33.99 on Friday. The stock has a market capitalization of $7.27 billion, a PE ratio of 21.93, a price-to-earnings-growth ratio of 2.05 and a beta of 1.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 1.53 and a quick ratio of 1.11. Axalta Coating Systems has a fifty-two week low of $24.94 and a fifty-two week high of $38.61. The business’s 50-day simple moving average is $34.00 and its 200-day simple moving average is $32.34.
Axalta Coating Systems (NYSE:AXTA – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The specialty chemicals company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.07). Axalta Coating Systems had a net margin of 6.46% and a return on equity of 21.28%. The firm had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.33 billion. During the same period in the prior year, the company posted $0.67 earnings per share. The company’s revenue for the quarter was up 1.8% compared to the same quarter last year. Sell-side analysts expect that Axalta Coating Systems will post 2.45 earnings per share for the current fiscal year.
Institutional Trading of Axalta Coating Systems
Several institutional investors and hedge funds have recently bought and sold shares of AXTA. Aurora Investment Counsel purchased a new stake in Axalta Coating Systems in the 2nd quarter valued at approximately $1,749,000. MAC Alpha Capital Management LP raised its holdings in shares of Axalta Coating Systems by 45.9% during the 2nd quarter. MAC Alpha Capital Management LP now owns 645,643 shares of the specialty chemicals company’s stock valued at $22,096,000 after purchasing an additional 203,243 shares in the last quarter. Amundi lifted its position in Axalta Coating Systems by 32.0% in the second quarter. Amundi now owns 841,326 shares of the specialty chemicals company’s stock worth $28,790,000 after purchasing an additional 203,829 shares during the period. Bank of America Corp DE acquired a new stake in Axalta Coating Systems in the second quarter worth about $19,763,000. Finally, Public Employees Retirement System of Ohio bought a new stake in Axalta Coating Systems in the 2nd quarter valued at approximately $2,261,000. 98.28% of the stock is currently owned by hedge funds and other institutional investors.
Key Stories Impacting Axalta Coating Systems
Here are the key news stories impacting Axalta Coating Systems this week:
- Positive Sentiment: Barclays lowered its price target modestly from $45 to $44 but maintained an “overweight” rating, implying approximately 29.5% potential upside from the referenced price. Barclays lowers Axalta price target
- Positive Sentiment: Axalta guided to approximately $1.10 billion-$1.11 billion in 2026 adjusted EBITDA and forecast fourth-quarter adjusted EPS of about $0.55, giving investors visibility into its near-term profitability expectations. Axalta guidance for 2026 EBITDA and fourth-quarter EPS
- Neutral Sentiment: Management reported third-quarter revenue of approximately $1.31 billion, up 1.8% year over year, while net income was about $95 million. The results indicate continued top-line growth but limited earnings momentum. Axalta third-quarter earnings results
- Negative Sentiment: Third-quarter adjusted EPS was $0.63, below consensus estimates near $0.70-$0.71 and down from $0.67 a year earlier. Revenue also missed expectations of roughly $1.33 billion, increasing concerns about margins and demand. Axalta third-quarter earnings and revenue miss
- Positive Sentiment: Ariel Global Fund highlighted potential cost savings from Axalta’s proposed merger with Akzo Nobel, offering a possible longer-term catalyst if the transaction produces expected synergies. Ariel Global Fund discusses Axalta and Akzo Nobel merger
About Axalta Coating Systems
Axalta Coating Systems Ltd. (NYSE: AXTA) develops, manufactures and sells coatings and coating technologies designed to protect, enhance and improve the appearance of vehicles, equipment and industrial products. Its offerings include liquid, powder and electrocoat products, along with related color-management tools, application technologies and technical services.
The company serves several markets, including automotive original equipment manufacturers, automotive refinish businesses, commercial transportation, industrial equipment, architecture and general manufacturing.
Recommended Stories
- Five stocks we like better than Axalta Coating Systems
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?